Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contact:

Michael W. Rogers Brooke D. Wagner

Executive Vice President and CFO VP, Corp. Communications

(781) 861-8444 (781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4FAA Grants Comment Extension at the Request of AMA 2ORNL study reveals new characteristics of complex oxide surfaces 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... - YM BioSciences Inc. (NYSE Alternext US:YMI, ... develops and commercializes differentiated products for patients ... clearance from Canadian regulatory authorities to initiate ... nimotuzumab, its EGFR-targeting antibody, in combination with ...
... Start of Q4 2008 , - Evaluation of strategic alternatives ... RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext ... reduction-in-force in an effort to extend its remaining cash and ... a reduction implemented in October 2008. In all, the ...
... Jan. 5 LightLab Imaging Inc. today,announced ... past year that are,the culmination of sustained ... These advances significantly increase the Company,s leadership,position ... OCT is a new,high-resolution, high-speed imaging ...
Cached Biology Technology:YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5LightLab Imaging Leads Global Advancement of Intracoronary Imaging 2LightLab Imaging Leads Global Advancement of Intracoronary Imaging 3
(Date:7/28/2014)... U.S. cities that have seen an increase in so-called ... closures, overwhelmed storm drains and compromised infrastructure--are on the ... , This nuisance flooding, caused by rising sea levels, ... and 925 percent since the 1960s. , The report, ... the United States, also finds Annapolis and Baltimore, Maryland, ...
(Date:7/28/2014)... found that 73 percent of adult survivors of childhood ... syndrome and related health problems by failing to follow ... issue of the journal Cancer . , Almost ... cancer in the study had metabolic syndrome, an umbrella ... abdominal obesity, elevated triglyceride and other abnormalities that often ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Interfering with interferon 2
... during deployments, U.S. Army units can gain tactical ... and post-conflict operations, and boost overall mission success, ... The study finds that commanders have not ... despite the effect environmental conditions can have on ...
... 23, 2008 Researchers at Sentara Cardiovascular Research Institute begin ... effectiveness of stents to open airways of patients with ... The EASE (Exhale Airway Stents for Emphysema) Trial ... to create new pathways to release trapped air from ...
... out of every three Americans is obese. These individuals are ... to other health problems, such as diabetes. ... the muscle. As a result, accumulated fat by-products inside ... of fat by-products, fat must either be oxidized (burned, as ...
Cached Biology News:Army can boost mission success by better managing 2Army can boost mission success by better managing 3Army can boost mission success by better managing 4Sentara begins international trial -- open at only 24 US locations 2For insulin sensitive overweight patients, 1 session of exercise improves metabolic health 2
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Prepared in distilled water....
Biology Products: